Conatus appoints Corporate Development head

pharmafile | July 18, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Conatus, emricasan 

Conatus Pharmaceuticals has announced the appointment of Daniel Ripley as head of Corporate Development.

Ripley will lead the commercialisation strategy and development and act as the internal co-ordinator on the firm’s lead fibrotic disease drug candidate emricasan.

“Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering early-to-late stage products”, said Steven Mento, president and chief executive of Conatus.

“His varied experience in drug development transactions will be particularly important as we move forward with the development of emricasan, our first-in-class caspase inhibitor, into Phase III clinical trials for acute liver failure and liver fibrosis, and the related co-ordination of its commercialisation activities”.

For more than a decade, Ripley has been involved with emerging growth life science companies. His experiences include M&A, technology licenses and alliance transactions with pharma companies.  He was instrumental in business negotiations at Kalypsys, Inc. and Isis Pharmaceuticals where he closed over $350 million in transactions.

Related Content

Novartis seals two deals to bolster drug pipeline

Novartis has consolidated its ophthalmology position by acquiring Encore Vision, a Fort Worth-based US company. …

Latest content